Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $368.0 million.

  • Rocket Pharmaceuticals' Liabilities and Shareholders Equity fell 651.66% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 619.68%. This contributed to the annual value of $527.7 million for FY2024, which is 682.29% down from last year.
  • Rocket Pharmaceuticals' Liabilities and Shareholders Equity amounted to $368.0 million in Q3 2025, which was down 651.66% from $421.0 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $598.8 million during Q3 2023, with a 5-year trough of $368.0 million in Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $497.0 million (2021), whereas its average is $487.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 5804.69% in 2021, then tumbled by 3424.97% in 2024.
  • Rocket Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $497.0 million in 2021, then grew by 11.02% to $551.8 million in 2022, then grew by 2.63% to $566.3 million in 2023, then dropped by 6.82% to $527.7 million in 2024, then tumbled by 30.26% to $368.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $368.0 million for Q3 2025, versus $421.0 million for Q2 2025 and $471.1 million for Q1 2025.